ARCoV vaccine is being developed by Chinese researchers at the Academy of Military Medical Sciences, Suzhou Abogen Biosciences, and Walvax Biotechnology.Current status: The vaccine is under a phase I trial in China.Mode of Action: ARCoV is an mRNA-based vaccine that carries the genetic information for encoding the disease-specific antigen to trigger the body’s immune system.